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Abstract
Objective—Determine clinical and neuropathological outcomes following a clinical diagnosis of 
mild cognitive impairment (MCI).
Methods—Data were drawn from a large autopsy series (N=1,337) of individuals followed 
longitudinally from normal or MCI status to death, derived from four Alzheimer’s Disease (AD) 
Centers in the United States.
Results—Mean follow-up was 7.9 years. Of the 874 individuals ever diagnosed with MCI, final 
clinical diagnoses were varied: 39.2% died with an MCI diagnosis, 46.8% with a dementia 
diagnosis, and 13.9% died with a diagnosis of intact cognition. The latter group had pathological 
features resembling those with a final clinical diagnosis of MCI. In terms of non-AD pathologies, 
both primary age-related tauopathy (p<0.05) and brain arteriolosclerosis pathology (p<0.001) were 
more severe in MCI than cognitively intact controls. Among the group that remained MCI until 
death, Mixed AD neuropathologic changes (ADNC) (≥1 comorbid pathology) was more frequent 
than Pure ADNC pathology (55% vs. 22%); “suspected non-Alzheimer’s pathology” (SNAP) 
comprised the remaining 22% of cases. A majority (74%) of subjects who died with MCI were 
without “high” level ADNC, Lewy body disease, or hippocampal sclerosis pathologies; this group 
was enriched in cerebrovascular pathologies. Subjects who died with dementia and were without 
severe neurodegenerative pathologies tended to have cerebrovascular pathology and carry the MCI 
diagnosis for a longer interval.
Interpretation—MCI diagnosis usually was associated with comorbid neuropathologies; less 
than one-quarter of MCI cases showed “pure” AD at autopsy.
INTRODUCTION
Mild cognitive impairment (MCI) is a clinical term referring to a portion of the cognitive 
continuum between intact (or “normal”) cognition and dementia. By definition, individuals 
with MCI are not demented; have cognitive deficits that may or may not include memory 
impairment; and are functionally fairly intact in terms of activities of daily living [1]. Most 
estimates of MCI prevalence among adults over age 60 range between 16% and 20% of the 
population [2].
MCI often precedes dementia due to Alzheimer’s disease (AD), but persons diagnosed with 
MCI may later be diagnosed as cognitively normal, remain diagnosed with MCI until death, 
or in many cases progress to clinical dementia due to non-AD brain diseases [3]. Studies of 
MCI suggest an annual progression rate to dementia of about 10% when conducted in 
specialist settings and about 5% when conducted in community settings [3]. Such rates 
imply that after 10 years of follow-up, many MCI cases will not progress to dementia; 
however, in this meta-analysis of MCI transition [3], studies with less than three years of 
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follow-up were excluded. Progression rates and survival time in MCI depend on many 
factors, including severity at diagnosis and diagnostic criteria [4,5], but the role of specific 
neuropathologies in progression rates is not clear.
Prior MCI studies underscore disease heterogeneity underlying this clinical condition [6–8]. 
For example, up to 30% of community-based MCI subjects have biomarker profiles that are 
consistent with neurodegeneration but inconsistent with AD (i.e., suspected non-Alzheimer 
pathophysiology or SNAP) [9]. Prior clinical-pathologic studies have reported that MCI is 
often associated with mixed pathologies [10], and there have been recent advances in the 
study of non-AD pathologies. For example, there is new understanding of the frequency of 
hippocampal sclerosis of aging (HS-Aging) [11], primary age-related tauopathy (PART) 
[12], and arteriolosclerosis [13], which may contribute to a clinical MCI diagnosis. These 
associations have not to our knowledge, yet been evaluated in large autopsy cohorts focusing 
on MCI. In the current study, we examined part of the Statistical Modeling of Aging and 
Risk of Transition (SMART) project database [14], analyzing longitudinal clinical data and 
neuropathologic outcomes of individuals from four Alzheimer’s Disease Centers (ADCs). 
The inclusion of multiple large autopsy cohorts with longitudinal follow-up provides the 
basis for a study of neuropathologic correlates of MCI among adults who died in old age.
METHODS
Subjects
Cases were drawn from the SMART database, a harmonized set of data elements drawn 
from 11 longitudinal studies of aging and cognition [14]. Based on availability of necessary 
variables, the following cohorts were included: Oregon Brain Aging Study [15], African 
American Dementia Project (see [14]), Klamath Exceptional Aging Project [16], Religious 
Orders Study [17], Rush Memory and Aging Project [18], Memory and Aging Project at 
Washington University [19], and Biologically Resilient Adults in Neurological Studies [20]. 
A total of 1,657 autopsies were initially available. Inclusion criteria for the current study 
were available autopsy data and a cognitive diagnosis (i.e., clinical assessment) within two 
years of death (this excluded 165 cases). Participants with dementia at study baseline, or 
who transitioned to dementia without an intervening MCI diagnosis, were also excluded 
(n=155). Individuals who died with final clinical diagnoses of intact cognition, MCI, or 
dementia were included. The included cohorts all originated from National Institute on 
Aging-funded ADCs. Research procedures were approved by Institutional Review Boards at 
each cohort’s home institution. All participants provided written informed consent.
MCI and dementia classification
To operationalize MCI over multiple research centers, an MCI designation indicated a 
clinical diagnosis of MCI (if available) or Clinical Dementia Rating (CDR) global score = 
0.5 [21]. Participants with a CDR global score of 0.5 often have AD pathology at autopsy 
regardless of subsequent CDR global scores of 0 [22]. Back transitions (e.g., a diagnosis of 
MCI followed by subsequent diagnosis of intact cognition) may be explained by many 
factors including inter-clinician differences in application of diagnostic criteria, within-
patient variability due to medical illness, polypharmacy, psychosocial factors, and/or 
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resistance to cognitive decline due to cognitive reserve [7,23]. Study participants were 
classified into four groups: 1) never diagnosed with MCI or dementia (“No Impairment”); 2) 
diagnosed with MCI but diagnosed with normal cognition at the last assessment before death 
(“MCI Reverters”); and 3) diagnosed with MCI and remained MCI until death (“Stable 
MCI”), and 4) diagnosed with MCI followed by subsequent diagnosis of dementia 
(“Dementia after MCI”). Centers used standard-at-the-time criteria for diagnoses of all-
cause dementia [24] and clinical AD [25].
Neuropathological classification
Autopsies were conducted within the original cohort studies [15,19,20,26]. 
Neuropathological assessments were performed blind to clinical data, and neuropathological 
data were scored according to a format of the National Alzheimer’s Coordinating Center 
(NACC) dataset, as described previously [14], because most SMART neuropathologists 
contribute to NACC (see https://www.alz.washington.edu/NONMEMBER/NP/rdd_np.pdf). 
Briefly, study neuropathologists made determinations of Braak NFT stage [27]; CERAD 
neuritic plaque rating [28]; HS-Aging [10]; presence of neocortical Lewy body disease [29]; 
arteriolosclerosis rating [12]; cerebral amyloid angiopathy (CAA) rating [30]; presence of 
large artery cerebral infarcts, lacunes, cortical microinfarcts, and hemorrhages. For 
comparisons that would be correlated with biomarkers that assess A® amyloidosis (as 
opposed to SNAP), CERAD neuritic amyloid plaque rating was used. PART was 
operationalized as CERAD neuritic plaque rating of None plus Braak NFT stage of I-IV 
[12]. “Large” infarcts were defined as any infarct with maximum diameter greater than 1 
cm; lacunes were defined as infarcts or hemorrhages 1 cm or less in diameter in the small 
parenchymal vessels, but visible to the naked eye; and, microinfarcts were defined as 
cortical infarcts detected microscopically only.
For comparisons of broader pathological profiles related to AD, we classified cases into 
three groups of amyloid determined pathologies based on the National Institute on Aging-
Alzheimer’s Association criteria for AD neuropathologic changes (ADNC). Applying these 
criteria, the presence of any diffuse plaque or any CERAD neuritic plaque of at least sparse 
results in a classification of at least low level ADNC [31]: Pure ADNC = ADNC of at least 
low plus the absence of any cerebrovascular pathology other than mild arteriolosclerosis, 
neocortical Lewy body pathology, HS-Aging, or PART; Mixed ADNC = ADNC of at least 
low plus the presence of any cerebrovascular pathology other than mild arteriolosclerosis, 
neocortical Lewy body pathology, HS-Aging, or PART; and pathologies that relate to the 
biomarker-defined entity of SNAP [32] = no diffuse plaques plus CERAD neuritic plaque 
rating of None, with or without any comorbid pathologies. We did not include CAA in these 
group classifications since CAA is not part of ADNC or PART consensus-based criteria, and 
it is currently unclear how CAA relates to neurodegeneration.
Statistical analysis
Participant characteristics and neuropathological outcomes were summarized using 
descriptive statistics within each group. Group demographic differences were assessed with 
analysis of variance (ANOVA) or chi-square tests. Adjusted between-group differences on 
neuropathological outcomes were assessed using binary or multinomial logistic regression 
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models. Covariates were age at death, sex, APOE (any ε4 vs. no ε4), years of education, 
survival time following MCI diagnosis, time between the last assessment and death, and 
research center. Since over 97% of the study sample was white, race was not considered as a 
covariate. Survival time was defined as the duration in years between the first diagnosis of 
MCI and either death or dementia, whichever came first.
To assess whether the survival time following an MCI diagnosis was associated with 
pathology type, participants in the Stable MCI and Dementia after MCI groups were divided 
into mutually exclusive major neurodegenerative disease and no major neurodegenerative 
disease groups. Cases with high level of ADNC (CERAD Moderate or Frequent plaques and 
Braak NFT stages V/VI), HS-Aging, or Lewy body disease were classified into the major 
neurodegeneration group, while all others were classified into the no major 
neurodegeneration group. To account for differences in observed survival times in prevalent 
vs. incident MCI, we included an indicator for baseline MCI in addition to the covariates 
listed above. Stable MCI and Dementia after MCI were analyzed separately.
RESULTS
Inclusion criteria yielded data from 1,337 autopsied subjects, stratified into four groups: No 
Impairment (N=463), MCI Reverters (N=122), Stable MCI (N=343), and Dementia after 
MCI (N=409). Participant characteristics are given in Table 1. Baseline age was significantly 
different in all groups (p<0.0001 for all pairwise comparisons except MCI Reverters vs. 
Stable MCI, where p=0.049). Mean age at death was greater than 85 years in all groups, but 
there were differences: the No Impairment group was significantly younger than any other 
group (p<0.0001 for all), and the Dementia after MCI group was significantly older than any 
other group (p<0.001 for all). There was no difference in age at death between the MCI 
Reverters and Stable MCI groups (Table 1). About 60% of the No Impairment and both MCI 
groups were female, compared to 67% in the dementia group (p=0.10). Mean educational 
attainment was similar in the groups and high overall in this sample (approximately 16 
years), but the MCI Reverters had a significantly higher education level than the No 
Impairment (p=0.02) and Stable MCI groups (p=0.004). Frequency of APOE-ε4 was 
significantly higher in the Stable MCI and Dementia after MCI groups compared to the No 
Impairment and MCI Reverters groups (p<0.0001). Approximately one-third of participants 
in both the MCI Reverters and Stable MCI groups were diagnosed with MCI at the baseline 
visit, while over 44% of participants in the Dementia after MCI group carried a baseline 
MCI diagnosis (p=0.003). Time on study was similar between the MCI Reverters and 
Dementia after MCI groups, but the No Impairment and Stable MCI groups were followed 
about 2 and 1.5 fewer years, respectively, than the Dementia after MCI group (p<0.0001). 
Time between last clinical assessment and death was restricted to less than or equal to two 
years; the mean time was less than one year in all groups, and was shorter for the Dementia 
after MCI group relative to the No Impairment (p<0.001), MCI Reverters (p=0.005), and 
Stable MCI (p<0.001) groups. The largest absolute difference translated to about one month. 
Mean time between annual assessments was just over one year in all groups with no 
significant differences. Mean final MMSE was the same between the No Impairment and 
MCI Reverters groups (p=0.83) and significantly different for all other pairwise comparisons 
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(p<0.0001). There were no significant differences in time between groups for the first 
diagnosis of MCI and dementia or death (p=0.27).
Distributions of neuropathological features are presented in Table 2. Adjusted odds ratios 
(OR) and 95% confidence intervals (95% CI) for MCI Reverters vs. No Impairment, Stable 
MCI, and Dementia after MCI are presented in Table 3. Confidence intervals that do not 
include 1.00 are statistically significant. Compared to the No Impairment group, MCI 
Reverters were only significantly more likely to have CERAD neuritic plaque ratings of 
Frequent. Compared to the Stable MCI group, MCI Reverters were significantly less likely 
to have Braak NFT stages of V/VI and moderate arteriolosclerosis. Compared to the 
Dementia after MCI group, the MCI Reverters were significantly less likely to have Braak 
NFT stages of V/VI, CERAD ratings of Moderate or Frequent, Lewy body disease, HS-
Aging, and moderate arteriolosclerosis.
Adjusted OR and 95% CI for Stable MCI vs. No Impairment and Dementia after MCI are 
presented in Table 4. Compared to the No Impairment group, the Stable MCI group was 
significantly more likely to have Braak NFT stages of V/VI, CERAD ratings or moderate or 
frequent, PART, Lewy body disease, and severe arteriolosclerosis. Compared to the 
Dementia after MCI group, the Stable MCI group was significantly less likely to have Braak 
NFT stages of V/VI, CERAD ratings of Moderate or Frequent, Lewy body disease, and HS-
Aging.
There was substantial heterogeneity of amyloid plaque pathology in the impaired groups 
(Figure 1). SNAP-type pathology was twice as common in the MCI Reverters and Stable 
MCI groups as in the Dementia after MCI group (~22% vs. 9%, p<0.0001). Pure ADNC was 
relatively constant across the groups, ranging from 17% in the Dementia after MCI group to 
24% in the MCI Reverters group (p=0.10), while Mixed ADNC was highest in the Dementia 
after MCI group (73%) and lowest in the MCI Reverters group (51%) (p<0.0001). Higher 
proportion of Braak NFT stage V/VI was associated with Dementia after MCI. Distributions 
of non-amyloid pathologies within the SNAP and Mixed ADNC categories are characterized 
in Table 5. For MCI Reverters, SNAP mostly comprised PART (43%) and PART plus 
cerebrovascular disease (CVD) (39.3%) pathologies. In the Stable MCI group PART plus 
CVD (73%) was the most common SNAP pathology, followed by PART alone (15%). In the 
Dementia after MCI group, PART plus CVD (60%) was again the most common SNAP 
pathology, followed by PART plus HS-Aging plus CVD (11%). For Mixed ADNC, ADNC 
plus CVD was the most commonly observed pathology type in all three groups: MCI 
Reverters (74%), Stable MCI (73%), and Dementia after MCI (62%).
Time elapsed between first diagnosis of MCI and death did not predict neurodegenerative vs. 
non-neurodegenerative pathology in the Stable MCI group (for a 1-year difference, 
OR=0.97, 95% CI 0.90–1.04). However, for the Dementia after MCI group, longer time in 
MCI (i.e., time between first diagnosis of MCI and first diagnosis of dementia) was 
associated with non-neurodegenerative pathologies (for a 1-year difference, OR=1.09, 95% 
CI 1.01–1.17).
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Here we report on a large series of autopsied research volunteers after extensive longitudinal 
clinical follow-up, focusing on outcomes after the first or only diagnosis of MCI. The study 
design enabled assessment of the distribution of neuropathological findings, the variability 
of progression through the clinical state of MCI, and the interactions among these factors. In 
this combined sample, only 22% of individuals who died with MCI (i.e., Stable MCI) had 
neuropathologic evidence of “pure” AD-type pathology. Importantly, we found novel and 
solid evidence that both severe arteriolosclerosis and PART pathologies are associated with a 
clinical MCI diagnosis. A second novel finding was that persons with MCI of longer 
duration, prior to dementia diagnosis, tended to have a profile of pathology more skewed 
toward cerebrovascular than neurodegenerative-type pathologies.
The themes that emerge from the interpretation of these results relate to the heterogeneous 
diseases that underlie MCI diagnoses, and the correspondingly varied clinical course of 
those diseases. The neuropathology of MCI has been addressed in prior studies that 
established that MCI is not necessarily a result of AD pathology in a given patient [8,10,33–
35]. However, this large autopsy series provides further direct evidence of disease 
heterogeneity underlying MCI: over half of the individuals who died with MCI had “mixed” 
pathologies with ADNC and other conditions, primarily CVD; 22% had non-AD conditions 
that would correspond to the concept of SNAP, similar to the 23% of participants with subtle 
cognitive change and who had neuropathology data in a prior study [36]; and only 22% of 
the cohort who died with MCI diagnoses had what could be described as “Pure ADNC”.
Persons with relatively severe PART (i.e., Braak NFT stages III-IV) were more likely to be 
diagnosed with MCI than they were to remain cognitively intact until death. Almost every 
elderly individual has some hippocampal NFTs, with or without other AD pathology [12]. 
However, among cases lacking cerebral neuritic plaques, there is variability in the NFT 
burden, i.e. severity of PART. In the first PART paper, we found that advanced PART (Braak 
NFT stages III-IV) was associated with worse cognition [11]. In the current study we now 
establish that PART is a common pathologic substrate for MCI. However, neuritic plaques 
(CERAD rating) were used to help operationalize PART, so we note that this would mean 
we are often describing “Possible” PART, rather than “Definite” PART according to the 
pathologic diagnostic criteria [12]. Further, it is not known how PART contributes to the 
clinical, biomarker-defined, phenomenon of SNAP, so more work is required at the interface 
of cognitive assessment, neuroimaging, cerebrospinal fluid analyses, and pathology.
The current study also suggests the importance of moderate to severe brain arteriolosclerosis 
in contributing to the transition from cognitively normal to MCI. Moderate arteriolosclerosis 
was more common among participants with Stable MCI and Dementia than among 
participants in the MCI Reverters group. Severe arteriolosclerosis was more common in the 
Stable MCI group compared to the No Impairment group, but the wide confidence interval 
for that result suggests the need for cautious interpretation. Previously, autopsy-confirmed 
severe brain arteriolosclerosis was shown to be associated with impaired global cognition 
[12,37]. Taken together, these findings indicate that small vessel changes may have an 
important impact in terms of cognitive status. We did not find strong evidence in the current 
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study that CAA was associated with transition to or from MCI when comorbid ADNC 
(plaques and tangles) were included in the statistical model.
In addition to cross-sectional analyses of the autopsy data, the long-term longitudinal data 
on these research subjects enabled characterization of differences in clinical course through 
MCI among individuals with and without neurodegenerative diseases (the latter comprising 
high level ADNC, Lewy body disease, and HS-Aging). Although these conditions are what 
most people would consider to be associated with MCI, a large majority of cases in the 
Stable MCI group (74%) lacked severe levels of these pathologies. Among those who 
progressed to dementia, those without high level ADNC, Lewy body disease, or HS-Aging 
tended to progress more slowly, with each additional year without a dementia diagnosis 
being associated with 9% increase in the odds that no severe burden of neurodegenerative 
disease pathologies would be observed at autopsy. This translates to a 54% increase in the 
odds of no severe neurodegenerative pathologies when the time between MCI and dementia 
diagnoses is 5 years. There have long been indications in the literature of a subgroup of MCI 
cases that does not progress to dementia [3], and cerebrovascular factors may help explain 
this phenomenon which is probably of interest to patients, clinicians, and clinical trial 
researchers.
The nature of the research sample and study design—combining results of autopsied 
subjects from multiple institutions—entailed both strengths and weaknesses. A key strength 
is the many subjects who were followed from normal cognition, and the large number of 
longitudinal visits for most subjects. However, there are basic challenges in recruitment bias 
for any sample of autopsied subjects. These include a relative lack of minority and other at-
risk populations. This autopsy series included mostly highly educated white females. We 
also note that the ages of the persons studied needs to be considered. A younger, more 
ethnically, racially, and socioeconomically diverse cohort would probably have different 
neuropathologic and clinical features. As we were not able to characterize MCI into 
amnestic vs. non-amnestic type, or single vs. multi-domain diagnoses, neuropathological 
underpinnings for different types of MCI diagnoses could not be assessed. Additionally, 
there is likely to be selection bias within each cohort in terms of who does and does not 
come to autopsy. There are some analytical methods for adjusting for this type of selection 
bias, such as inverse probability weighting [38]. Inverse probability weighting creates a 
pseudo-population by giving more weight to autopsied participants who were least likely to 
be autopsied, and less weight to participants who were most likely to be autopsied. We 
explored using inverse probability of autopsy weights to adjust for selection bias, but center 
effects and small cell sizes for some pathologies, such as severe arteriolosclerosis, led to 
unstable results. Thus, we present the weighted analyses in Supplemental Tables 1 and 2. We 
note that results were generally in the same direction in the both the unweighted and 
weighted analyses, and exceptions were mostly limited to the MCI Reverters analysis, which 
had the smallest sample size. The weighted analyses suggests a stronger association between 
MCI and both arteriolosclerosis and CAA than was observed in the unweighted analyses. 
Further study into the association between these two pathologies and MCI is warranted.
Additionally, the stage of MCI (e.g., early or late) at first diagnosis likely varied among 
participants, particularly given the mixture of clinical diagnosis and CDR ratings that made 
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up our case operationalizations. This has implications for the expected survival time in MCI 
[4,5]. However, prior research has demonstrated that individuals with any instances of CDR 
= 0.5 show increased AD-type neuropathological burden at autopsy [21], suggesting that 
these classifications are indicative of underlying disease. Further, classification of the 
clinical state was independent of autopsy findings, which suggests that bias due to 
misclassification would be nondifferential.
Additionally, while we had an emphasis on including state-of-the-art neuropathologic 
assessment data, we did not include TDP-43 or argyrophilic grain disease (AGD) 
pathologies in the study due to inadequate collection and harmonization across centers. 
Since both TDP-43 and AGD pathologies have been shown to be associated with cognitive 
status [39–41], this probably led to insensitivity in parsing out causes of SNAP and 
delineating all the cases with “neurodegenerative conditions.” Moreover, the term “SNAP” 
was developed in the biomarker field, and as such, while it can be generalized to 
neuropathology, issues such as thresholds and cutoffs would be different, for example, in 
neuropathological cases versus subjects in imaging studies. This study also combined 
autopsied cases assessed by multiple neuropathologists, who had different methods and 
criteria for classifying neuropathology. However, this approach may better approximate the 
experience of community neuropathologists in comparison to an approach that employs only 
a single academic neuropathologist. Interrater variability also applies to the MCI diagnosis, 
which was done by different clinicians at different centers. Although we controlled for 
center in our analyses, there is likely to be additional variation that was not captured with 
this approach. A further implication of diagnostic variability is that the group of subjects 
diagnosed previously with MCI but who were diagnosed with intact cognition at the time of 
death should not be taken to be representative of all other patients carrying an MCI 
diagnosis. The true proportion of MCI diagnoses that would permanently revert to intact 
cognition is unknown.
We conclude that MCI is a clinical state that has heterogeneous underlying pathologies with 
a clinical course that varies according to those pathologies and likely also varies according 
to participant characteristics. Not only are different diseases linked to MCI, but, more often 
than not, the clinical condition reflects the impact of multiple brain diseases. These data 
highlight the complexity of brain changes in old age, and the importance of better 
biomarkers to help characterize the combination of mechanisms that underlie a given 
patient’s cognitive impairment.
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Distribution of major pathology types among participants who died after MCI diagnosis. 
SNAP = suspected non-Alzheimer’s pathology, ADNC = Alzheimer’s disease 
neuropathologic changes.
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Table 1








Baseline age, y 79.1±7.8 84.2±6.6 85.7±7.1 82.5±6.7
Age at death, y 85.9±7.3 89.2±6.2 89.5±6.6 91.5±6.1
Female (n %) 281 (60.7) 72 (59.0) 205 (60.0) 275 (67.2)
Education, y 15.8±3.4 16.6±3.5 15.6±3.7 16.1±3.5
APOE, ≥ 1 ε4 (n %) 76 (16.4) 21 (17.2) 76 (22.2) 128 (31.3)
Baseline diagnosis (n %)
 Intact cognition 463 (100) 86 (70.5) 221 (64.4) 228 (55.8)
 MCI 0 (0) 36 (29.5) 122 (35.6) 181 (44.3)
Time on study, y 6.9±4.7 8.9±4.5 7.5±4.5 9.0±4.2
Time from last diagnosis to death, y 0.7±0.4 0.7±.04 0.7±0.4 0.6±0.4
Time between clinical assessments, y 1.05±0.27 1.05±0.37 1.05±0.39 1.05±0.32
Final MMSEa 28.0±2.0 27.9±1.7 25.7±3.3 14.3±8.1
Median MCI Duration Timeb, y (IQR) – 5.1 (1.9, 9.3) 4.4 (1.7, 9.3) 4.1 (2.1, 8.1)
Note: results are mean±sd unless otherwise noted.
a
MMSE score is last score reported within two years of death (Normal: n=423; MCI Reverters: n=112; Stable MCI: n=300; Dementia after MCI: 
n=349);
b
duration time is time from first MCI diagnosis to either first dementia diagnosis (Dementia after MCI) or death (MCI Reverters and Stable MCI).
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Table 2









 0/I/II 202 (43.6) 34 (27.9) 85 (24.8) 48 (11.7)
 III/IV 195 (42.1) 74 (60.7) 187 (54.5) 183 (44.7)
 V/VI 22 (4.8) 10 (8.2) 61 (17.8) 171 (41.8)
CERAD neuritic plaque rating
 None 196 (42.3) 40 (32.8) 93 (27.1) 48 (11.7)
 Sparse 76 (16.4) 19 (15.6) 57 (16.6) 44 (10.8)
 Moderate 125 (27.0) 36 (29.5) 128 (37.3) 135 (33.0)
 Frequent 52 (11.2) 24 (19.7) 58 (16.9) 177 (43.3)
PARTa
 Braak NFT I/II 116 (65.9) 19 (48.7) 39 (43.8) 19 (44.2)
 Braak NFT III/IV 60 (34.1) 20 (51.3) 50 (56.2) 24 (55.8)
Lewy body disease 18 (3.9) 6 (4.9) 25 (7.3) 66 (16.1)
Hippocampal sclerosis of aging 12 (2.6) 7 (5.7) 18 (5.3) 66 (16.1)
Large artery infarct 70 (15.1) 20 (16.4) 59 (17.2) 97 (23.7)
Lacunar infarct 130 (28.1) 40 (32.8) 117 (34.1) 159 (38.9)
Microinfarct 96 (20.7) 22 (18.0) 78 (22.7) 104 (25.4)
Hemorrhage 56 (12.1) 10 (8.2) 30 (8.8) 26 (6.4)
Arteriolosclerosis
 None 137 (29.6) 13 (10.7) 31 (9.0) 27 (6.6)
 Mild 197 (42.6) 60 (49.2) 134 (39.1) 173 (42.3)
 Moderate 82 (17.7) 31 (25.4) 128 (37.3) 142 (34.7)
 Severe 8 (1.7) 4 (3.3) 25 (7.3) 33 (8.1)
Cerebral amyloid angiopathy
 None 179 (38.7) 29 (23.8) 115 (33.5) 88 (21.5)
 Mild 151 (32.6) 53 (43.4) 130 (37.9) 145 (35.5)
 Moderate 71 (15.3) 27 (22.1) 49 (14.3) 100 (24.5)
 Severe 32 (6.9) 7 (5.7) 31 (9.0) 62 (15.2)
a
PART = primary age-related tauopathy. PART cases are CERAD None.
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Table 3
Comparison of neuropathological features between participants who were diagnosed with MCI and but later 
died with a diagnosis of intact cognition (“MCI Reverters”), participants with no diagnosed cognitive 
impairment (“No Impairment”), participants who were diagnosed with MCI and remained MCI until death 
(“Stable MCI”), and participants who were diagnosed with MCI and later developed dementia (“Dementia 
after MCI”).
Characteristics
MCI Reverters vs. No 
Impairment
OR (95% CI)a
MCI Reverters vs. Stable MCI
OR (95% CI)a




 0/I/II ref ref ref
 III/IV 1.37 (0.57, 3.30) 0.89 (0.52, 1.52) 0.57 (0.30, 1.08)
 V/VI 1.24 (0.20, 7.84) 0.31 (0.12, 0.78) 0.08 (0.03, 0.20)
CERAD neuritic plaque rating
 None ref ref ref
 Sparse 1.86 (0.63, 5.55) 0.99 (0.50, 1.98) 0.64 (0.28, 1.50)
 Moderate 2.21 (0.83, 5.86) 0.74 (0.41, 1.33) 0.40 (0.21, 0.76)
 Frequent 4.33 (1.29, 14.53) 1.08 (0.53, 2.21) 0.18 (0.09, 0.38)
PARTb
 Braak NFT I/II ref ref ref
 Braak NFT III/IV 1.17 (0.31, 4.42) 0.84 (0.36, 1.95) 1.05 (0.32, 3.44)
Lewy body disease 0.93 (0.10, 8.98) 0.30 (0.08, 1.08) 0.13 (0.04, 0.43)
Hippocampal sclerosis of aging 0.40 (0.06, 2.48) 1.42 (0.54, 3.72) 0.35 (0.15, 0.81)
Large artery infarct 0.70 (0.25, 1.94) 0.97 (0.53, 1.76) 0.65 (0.37, 1.17)
Lacunar infarct 0.84 (0.38, 1.86) 0.89 (0.56, 1.42) 0.77 (0.48, 1.22)
Microinfarct 0.77 (0.29, 2.05) 0.85 (0.49, 1.49) 0.71 (0.41, 1.24)
Hemorrhage 0.50 (0.13, 1.91) 0.92 (0.41, 2.07) 1.22 (0.52, 2.90)
Arteriolosclerosis
 None ref ref ref
 Mild 0.75 (0.21, 2.67) 1.05 (0.44, 2.52) 0.68 (0.29, 1.63)
 Moderate 0.25 (0.05, 1.18) 0.29 (0.10, 0.80) 0.30 (0.11, 0.84)
 Severe 1.29 (0.05, 32.99) 0.24 (0.03, 2.09) 0.18 (0.03, 1.02)
Cerebral amyloid angiopathyc
 None ref ref ref
 Mild 1.02 (0.39, 2.70) 1.77 (0.96, 3.28) 1.74 (0.88, 3.44)
 Moderate 2.20 (0.58, 8.31) 2.37 (0.99, 5.69) 2.35 (0.95, 5.80)
 Severe 0.26 (0.02, 2.83) 0.86 (0.26, 2.82) 0.50 (0.15, 1.65)
Note:
a
Odds ratios are adjusted for age at death, sex, years of education, APOE, time in the MCI state prior to dementia or death, time between last 
assessment and death, and research center;
b
PART = primary age-related tauopathy. PART cases are CERAD None.
c
Odds ratios for Cerebral amyloid angiopathy are also adjusted for Braak NFT stage and CERAD neuritic plaque rating.
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Table 4
Comparison of neuropathological features between participants who were diagnosed with MCI and remained 
MCI until death (“Stable MCI”), participants with no diagnosed cognitive impairment (“No Impairment”), and 
participants who were diagnosed with MCI and later developed dementia (“Dementia after MCI”).
Characteristics
Stable MCI vs. No Impairment
OR (95% CI)a
Stable MCI vs. Dementia after MCI
OR (95% CI)a
Braak NFT stage
 0/I/II ref ref
 III/IV 1.53 (0.93, 2.53) 0.77 (0.49, 1.21)
 V/VI 5.20 (2.41, 11.23) 0.24 (0.14, 0.41)
CERAD neuritic plaque rating
 None ref ref
 Sparse 1.49 (0.77, 2.87) 0.85 (0.47, 1.54)
 Moderate 2.75 (1.61, 4.68) 0.62 (0.39, 0.98)
 Frequent 2.08 (1.00, 4.32) 0.17 (0.10, 0.29)
PARTb
 Braak NFT I/II ref ref
 Braak NFT III/IV 2.33 (1.01, 5.40) 1.52 (0.64, 3.61)
Lewy body disease 2.40 (1.00, 5.73) 0.39 (0.24, 0.66)
Hippocampal sclerosis of aging 1.76 (0.64, 4.88) 0.31 (0.18, 0.55)
Large artery infarct 1.05 (0.61, 1.82) 0.75 (0.51, 1.10)
Lacunar infarct 1.17 (0.76, 1.80) 0.84 (0.61, 1.17)
Microinfarct 1.01 (0.61, 1.68) 0.77 (0.53, 1.12)
Hemorrhage 1.14 (0.59, 2.19) 1.47 (0.82, 2.65)
Arteriolosclerosis
 None ref ref
 Mild 0.74 (0.36, 1.51) 0.80 (0.41, 1.55)
 Moderate 1.00 (0.44, 2.29) 0.72 (0.36, 1.40)
 Severe 7.36 (1.62, 33.49) 0.23 (0.06, 0.92)
Cerebral amyloid angiopathyc
 None ref ref
 Mild 0.78 (0.45, 1.34) 0.97 (0.61, 1.54)
 Moderate 0.59 (0.27, 1.31) 0.89 (0.49, 1.64)
 Severe 1.10 (0.42, 2.87) 0.59 (0.29, 1.20)
Note:
a
Odds ratios are adjusted for age at death, sex, years of education, APOE, time in the MCI state prior to dementia or death, time between last 
assessment and death, and research center;
b
PART = primary age-related tauopathy. PART cases are CERAD None.
c
Odds ratios for Cerebral amyloid angiopathy are also adjusted for Braak NFT stage and CERAD neuritic plaque rating.
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Table 5








 PART 12 (42.9) 11 (14.9) 2 (5.4)
 CVD 1 (3.6) 3 (4.1) 3 (8.1)
 PART + Lewy body disease 0 2 (2.7) 0
 PART + HS-Aging 1 (3.6) 0 1 (2.7)
 PART + CVD 11 (39.3) 54 (73.0) 22 (59.5)
 PART + Lewy body disease + HS-Aging 0 0 2 (5.4)
 PART + Lewy body disease + CVD 1 (3.6) 2 (2.7) 3 (8.1)
 PART + HS-Aging + CVD 2 (7.1) 1 (1.4) 4 (10.8)








 PART 1 (1.6) 4 (2.1) 1 (0.3)
 Lewy body disease 0 3 (1.6) 17 (3.1)
 HS-Aging 1 (1.6) 7 (3.7) 13 (4.4)
 CVD 46 (74.2) 138 (73.4) 184 (61.5)
 PART + CVD 6 (9.7) 10 (5.3) 7 (2.3)
 PART + Lewy body disease + CVD 1 (1.6) 0 1 (1.6)
 PART + HS-Aging + CVD 0 2 (1.1) 0
 Lewy body disease + HS-Aging 0 0 3 (1.0)
 Lewy body disease + CVD 4 (6.5) 16 (8.5) 31 (10.4)
 Lewy body disease + HS-Aging + CVD 0 0 9 (3.0)
 HS-Aging + CVD 3 (4.8) 8 (4.3) 33 (11.0)
Note: SNAP = suspected non-Alzheimer pathology; ADNC = Alzheimer’s disease neuropathologic changes; CVD = cerebrovascular disease; HS-
Aging = hippocampal sclerosis of aging; PART = primary age-related tauopathy.
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